多西他赛联合顺铂治疗晚期非小细胞肺癌37例临床研究

The clinical study of docetaxei combined with cisplatin regimen in treatment of advanced non-small-cell lung cancer

目的观察多西他赛联合顺铂（DP方案）治疗晚期非小细胞肺癌（NSCLC）的临床疗效和不良反应。方法37例晚期NSCLC患者应用DP方案化疗，21d为1个周期，至少2个周期后评价疗效。结果全组有效率为35．1％，ⅢB期有效率为50．0％，Ⅳ期有效率为29．6％。鳞癌的有效率为42．9％，腺癌的有效率为35．0％。不良反应主要表现为恶心呕吐、骨髓抑制、腹泻、肝功能损害，发生率分别为58．7％、41．3％、11．9％、2．8％。重度（Ⅲ～Ⅳ度）的不良反应发生率为19．3％。结论DP方案治疗晚期NSCLC，疗效较好，不良反应轻，患者耐受性好。

Objective To investigate the efficacy and toxicity of advanced non-small-cell lung cancer （NSCLC） treated by docetaxel （DOC） combined with cisplatin （DDP）,DP regimen. Methods Thirty-seven patients with advanced NSCLC were studied retrospectively. They were treated with DP regimen.The dose were DOC 75 mg/m^2 day 1-8,and DDP 75 mg/m^2 day 1-3. The patients were repeatedly treated every 3 weeks and evaluated the efficacy after 2 cycles at least. Ressults The overall response rate （RR） was 35.1%. The RR of the stage ⅢB was 50.0%,and the RR of the stage Ⅳ was 29.6%.The RR of the squamous cell carcinoma was 42.9%, and the RR of the adenocarcinoma was 35.0%. Major toxicity were nausea, myelosuppression, diarrhea, hepatic lesion. Their occurrence rate were 58.7%, 41.3%, 11.9%, 2.8% respectively. The severe toxicity （Ⅲ-Ⅳ） was 19.3%. Conclusion DP regimen for advanced NSCLC shows a good curative effect and low toxicity. It deserves further clinical application.